Skip to main content
Spotify for Podcasters
The Uromigos

The Uromigos

By The Uromigos

Broadcasting the latest developments in GU cancer
Available on
Apple Podcasts Logo
Google Podcasts Logo
Pocket Casts Logo
RadioPublic Logo
Spotify Logo
Currently playing episode

Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1

The UromigosAug 15, 2023

00:00
46:19
Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial

Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial

Jim Catto describes the 17 yr follow up data from this large prostate cancer study.
Sep 27, 202329:52
Episode 263: Toni Choueiri and papillary renal cancer

Episode 263: Toni Choueiri and papillary renal cancer

We describes progress in system therapy for advanced papillary RCC. Opportunities and challenges around personalised therapy are discussed
Sep 20, 202336:21
Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC.

Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC.

Susan Slovin describes her JCO investigator initiated R2 study which show the addition of cabazitaxel to abiraterone may be of benefit in CRPC
Sep 12, 202330:35
Episode 261: part 2 ctDNA in bladder cancer

Episode 261: part 2 ctDNA in bladder cancer

Matt Galsky completes the discussion on the rapidly moving topic.
Sep 04, 202340:29
Episode 260: Celeste Simon: how to make a career in translation science work.

Episode 260: Celeste Simon: how to make a career in translation science work.

Celeste shares her thoughts on her career in the lab, collaboration and working with clinicians. She also talks about things that went well and things that went less wells
Aug 30, 202326:25
Episode 259: Cystectomy for bladder cancer

Episode 259: Cystectomy for bladder cancer

Jim Catto defends the virtues of cystectomy after last weeks radiotherapy for MIBC podcast with Ananya


Aug 24, 202325:29
Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1

Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1

Ananya Choudhury discussed the evidence for RT/TMT instead of surgery in muscle invasive bladder cancer. Regina Barragan-Carrillo (Golden Ticket Winner) introduces the podcast.
Aug 15, 202346:19
Episode 257: Chana Weinstock from the FDA

Episode 257: Chana Weinstock from the FDA

Chana discusses her role at the FDA, how it functions and answers questions on topical issues.
Aug 07, 202336:22
Episode 256: ctDNA in urothelial studies.

Episode 256: ctDNA in urothelial studies.

Mat Galski discusses the past, present and future of ctDNA in this disease.
Jul 27, 202337:46
Episode 255: How to get an academic paper accepted

Episode 255: How to get an academic paper accepted

Walt Stadler gives tips to writing papers and navigating the review process.
Jul 26, 202330:22
Episode 254: New RCC studies at KCRS 2023 with Laurence Albiges

Episode 254: New RCC studies at KCRS 2023 with Laurence Albiges

Laurence Albiges discusses biomarker studies, new combinations and new therapies which were covered in the KCRS23 meeting in the ‘new studies' session.


Jul 17, 202328:13
Episode 253: Patients' perspectives on adjuvant and 1st line RCC

Episode 253: Patients' perspectives on adjuvant and 1st line RCC

Rachel Giles (chair of IKCC) describes her data from patients on these topics in RCC
Jul 13, 202327:03
Episode 252: Talazoparib and its FDA approval in CRPC

Episode 252: Talazoparib and its FDA approval in CRPC

Neeraj Agarwal describes the TALAPRO-2 study and relevance of the HRR biomarker in the 2 cohorts presented. A discussion regarding other PARPis and BRCA1/2 occurs
Jul 04, 202332:14
Episode 251: Final part of VEGF/TKI vs IPI/NIVO discussion

Episode 251: Final part of VEGF/TKI vs IPI/NIVO discussion

Meredith Regan and David McDermott try to make sense of it all but are unexpectedly interrupted. PFS2 and TFS are covered along with previously discussed endpoints.
Jun 26, 202350:36
Episode 250: Bob Motzer discusses IPI/Nivo vs VEGF/PD1

Episode 250: Bob Motzer discusses IPI/Nivo vs VEGF/PD1

After the discussion with Mike Atkins, Bob Motzer gives his perspective of the 1st line renal cancer situation .
Jun 18, 202330:13
Episode 249: ASCO 2023 emergency podcast IPI/NIVO vs VEGF/PD1 in kidney cancer

Episode 249: ASCO 2023 emergency podcast IPI/NIVO vs VEGF/PD1 in kidney cancer

Prompted by a question during the oral kidney cancer session at ASCO, Mike Atkins explains his position. Disagreement prevails.
Jun 18, 202336:50
Episode 248: ASCO23 GU highlights

Episode 248: ASCO23 GU highlights

Silke Gillessen joins Brian and Tom for a quick round up.
Jun 14, 202335:28
Episode 246: ASCO 2023: EV pembro and erdafitinib +/- cetrelimab in 1st line UC

Episode 246: ASCO 2023: EV pembro and erdafitinib +/- cetrelimab in 1st line UC

Shilpa Gupta discussed these 2 oral abstracts from ASCO
Jun 05, 202324:27
Episode 245: ASCO 2023 - CONTACT-03 cabozantinib +/- atezolizumab in renal cancer

Episode 245: ASCO 2023 - CONTACT-03 cabozantinib +/- atezolizumab in renal cancer

Toni Choueiri describes the results of this renal cancer trial exploring rechallange with immune therapy
Jun 05, 202327:47
Episode 244: ASCO 2023 PEACE-1 in CRPC

Episode 244: ASCO 2023 PEACE-1 in CRPC

Karim Fizazi described the radiotherapy component of this study.
Jun 05, 202324:56
Episode 243: ASCO 2023 TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide

Episode 243: ASCO 2023 TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide

ASCO 2023: TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide
Jun 05, 202316:16
Episode 242: ASCO 2023 THOR study - erdafitinib vs chemo in bladder cancer

Episode 242: ASCO 2023 THOR study - erdafitinib vs chemo in bladder cancer

yohann Loriot discusses this practice changing trial
Jun 05, 202326:29
Episode 241: Statistics for clinical trials

Episode 241: Statistics for clinical trials

Meredith Regan describes how best to interpret KM curves and comparative analysis.
Jun 01, 202338:11
Episode 240: Preview of GU Cancer at ASCO 2023

Episode 240: Preview of GU Cancer at ASCO 2023

A look forward to bladder, kidney and prostate cancer sessions at ASCO 2023


May 30, 202327:02
Episode 239: The STAMPEDE trial

Episode 239: The STAMPEDE trial

Nick James describes the success this practice changing multi arm prostate study with an adaptive design
May 22, 202302:16:08
Episode 238: Paper of the month: Biomarkers for neoadjuvant PD(L)1 therapy

Episode 238: Paper of the month: Biomarkers for neoadjuvant PD(L)1 therapy

Josh Meeks describes his teams Nature Communications paper (including 11 supplementary figures).


May 14, 202324:52
Episode 237: 2023 AUA Highlights

Episode 237: 2023 AUA Highlights

Tom, who failed to invite a guest, quizzes Brian on the new data from the meeting he attended.

May 09, 202326:17
Episode 236: ODAC for olaparib

Episode 236: ODAC for olaparib

Jorge A. Garcia, MD, FACP, chairperson of the Oncologic Drugs Advisory Committee (ODAC) for the US Food & Drug Administration, shared insight on the recent ODAC meeting where members determined that olaparib plus abiraterone as an upfront treatment for mCRPC should be restricted to patients with BRCA mutations. Dr. Garcia is a medical oncologist at the University Hospitals Seidman Cancer Center and is the center’s George & Edith Richman Distinguished Scientist Chair, as well as Chief of their Solid Tumor Oncology division.
May 02, 202333:50
Episode 235: Danny Heng and the IMDC classification in renal cancer

Episode 235: Danny Heng and the IMDC classification in renal cancer

Daniel Heng, MD, MPH, FRCPC, joins us to discuss IMDC classification for renal cell carcinoma and the treatment of patients with favorable risk disease. Dr. Heng is a professor of oncology at the University of Calgary in Alberta, Canada, and is the leader of the International mRCC Database Consortium (IMDC) which consists of data from over 9,200 patients with mRCC treated with targeted therapies from over 38 cancer centers worldwide.


Apr 24, 202328:01
Episode 234: Amar Kishan, MD, on Neoadjuvant or Adjuvant Radiotherapy for Prostate Cancer

Episode 234: Amar Kishan, MD, on Neoadjuvant or Adjuvant Radiotherapy for Prostate Cancer

In the first part of our Hollywood tour, Amar Kishan, MD, joins us to discuss his recent meta-analysis published in the Journal of Clinical Oncology on the effects of concurrent adjuvant sequencing versus neoadjuvant concurrent sequencing. Dr. Kishan also gives an overview of the added benefit that androgen deprivation therapy provides when combined with radiation therapy. Dr. Kishan is the Vice Chair of Clinical and Translational Research and Chief of GU Radiotherapy at the University of California, Los Angeles.


Apr 19, 202320:35
Episode 233: Destaques da 14ª reunião internacional brasileira de câncer urológico

Episode 233: Destaques da 14ª reunião internacional brasileira de câncer urológico

Karine Trindade e Fernando Maluf dão uma visão geral da reunião e dos avanços na investigação do câncer no Brasil






Apr 15, 202315:34
Episode 232: Belzutifan in early and late renal cancer

Episode 232: Belzutifan in early and late renal cancer

We’re joined by Toni Choueiri, MD, and Brian Shuch, MD, to discuss several studies on the use of belzutifan alone and in combination with other treatments in patients with early and late-stage renal cancer, as well as patients with Von Hippel-Lindau syndrome and advanced sporadic RCC. Dr. Shuch is the director of the University of California, Los Angeles’s Kidney Cancer Program and is the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research. Dr. Choueiri is the director of Dana-Farber Cancer Institute’s Lank Center for Genitourinary Oncology, and serves as medical director of Dana-Farber’s International Strategic Initiatives.

Apr 14, 202331:12
Episode 231: Ursula Vogl, MD in the Rising Star Series

Episode 231: Ursula Vogl, MD in the Rising Star Series

Ursula Vogl, MD, discusses her career in the prostate cancer and renal cell cancer fields, as well as recent projects that she has contributed to including a prostate cancer investigator-led trial on patients with PSA-only progression. Dr. Vogl is a senior physician oncologist at the Istituto Oncologico della Svizzera Italiana in Switzerland, and is the clinical head of the Prostate Cancer Center of Southern Switzerland.


Apr 05, 202328:15
Episode 230: FGFR Inhibition in NMIBC With Sia Daneshmand

Episode 230: FGFR Inhibition in NMIBC With Sia Daneshmand

Sia Daneshmand, MD, joins the show to review 2 studies on the use of erdafitinib for the treatment of non-muscle invasive bladder cancer, including the THOR-2 trial investigating erdafitinib versus intravesical chemotherapy in patients who received BCG therapy and recurred with high-risk NMIBC. Dr. Daneshmand is the director of urologic oncology at the Keck School of Medicine, University of Southern California, Los Angeles.

Mar 28, 202326:04
Episode 229: Kala Sridhar, MD on PET in Early Bladder Cancer

Episode 229: Kala Sridhar, MD on PET in Early Bladder Cancer

Kala Sridhar, MD discusses her recent work on the PET MUSE study on the impact of PET imaging in muscle-invasive urothelial carcinoma, as well as a neoadjuvant sub-study. Dr. Sridhar is a Genitourinary Medical Oncologist at the Princess Margaret Cancer Center in Toronto, and a Professor in the Department of Medicine at the University of Toronto.


Mar 20, 202325:43
Episode 228: Karine Tawagi, MD in the Rising Star Series

Episode 228: Karine Tawagi, MD in the Rising Star Series

Karine Tawagi, MD, Assistant Professor of Clinical Medicine and Associate Fellowship Program Director at the University of Illinois in Chicago, joins us for a new episode of their Rising Star series. Dr. Tawagi discusses her work in immune-related toxicities, and her focus on bladder,


Mar 15, 202323:19
Episode 227: 2023 ASCO GU Bladder Highlights and Paper of the Month with Michiel Van der Heijden

Episode 227: 2023 ASCO GU Bladder Highlights and Paper of the Month with Michiel Van der Heijden

Michiel Van der Heijden, MD, PhD, joined Tus to review bladder cancer presentations from the 2023 ASCO GU Cancers Symposium, including the phase 1B NABUCCO trial on the use of high- or low-dose preoperative ipilimumab with nivolumab for stage III urothelial cancer, as well as his paper on the use of predictive biomarkers for survival benefit with ramucirumab in the RANGE trial. Dr. Van der Heijden is a medical oncologist research group leader at The Netherlands Cancer Institute, focusing on the improvement of bladder cancer treatment.


Mar 06, 202331:59
Episode 226: 2023 ASCO GU Prostate and RCC Highlights With Dan George

Episode 226: 2023 ASCO GU Prostate and RCC Highlights With Dan George

The Uromigos are joined by Daniel George, MD, to review RCC and prostate cancer presentations from the 2023 ASCO GU Cancers Symposium, including triplet versus doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial. Dr. George is a medical oncologist at Duke Health, specializing in genitourinary malignancies.

Feb 27, 202325:31
Episode 225: ASCO GU 2023: Brian Shuch, MD discusses the ZIRCON Phase III Study of girentuximab PET/CT imaging in RCC

Episode 225: ASCO GU 2023: Brian Shuch, MD discusses the ZIRCON Phase III Study of girentuximab PET/CT imaging in RCC

Brian Shuch, MD, discusses the ZIRCON Phase III kidney cancer imaging study to determine the identification and characterization abilities of TLX250-CDx for clear cell renal cell carcinoma that was presented at the 2023 ASCO GU Cancers Symposium. Dr. Shuch is the Director of the University of California, Los Angeles Kidney Cancer Program, and an Associate Professor of Urology.

Feb 20, 202324:48
Episode 224: ASCO GU 2023: discussing miR371 for Germ Cell Tumors with Christian Kollmannsberger

Episode 224: ASCO GU 2023: discussing miR371 for Germ Cell Tumors with Christian Kollmannsberger

The Uromigos are joined by Christian Kollmannsberger, MD, FRCPC, to discuss his presentation at the ASCO GU Cancers Symposium on utilizing miR371 as a biomarker for germ cell tumors to help optimize patient management by improving decision-making. Dr. Kollmannsberger is a medical oncologist at the British Columbia Cancer Agency Vancouver Cancer Centre, and Clinical Professor at the University of British Columbia.

Feb 20, 202327:18
Episode 223: ASCO GU 2023: Discussing KEYNOTE-057 with Andrea Necchi, MD

Episode 223: ASCO GU 2023: Discussing KEYNOTE-057 with Andrea Necchi, MD

The Uromigos met with Andrea Necchi, MD at the 2023 ASCO GU Cancers Symposium to discuss results of the phase 2 KEYNOTE-057 study on the use of pembrolizumab monotherapy for patients with high-risk non-muscle-invasive bladder cancer who are unresponsive to bacillus Calmette–Guérin therapy. Dr. Necchi is an Associate Professor at Università Vita-Salute San Raffaele, Head of Genitourinary Medical Oncology at Ospedale San Raffaele, and Vice President of the Global Society of Rare GU Tumors.

Feb 17, 202324:28
Episode 222: ASCO GU 2023: New Data From IMvigor130 with Enrique Grande, MD

Episode 222: ASCO GU 2023: New Data From IMvigor130 with Enrique Grande, MD

Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the phase 3 IMvigor130 study that examined 3 treatments for patients with metastatic urothelial carcinoma: chemotherapy, single-agent atezolizumab, or a combination treatment of atezolizumab plus chemotherapy. Dr. Grande is Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Cancer Center Madrid.

Feb 17, 202320:09
Episode 221: ASCO GU 2023: Matt Galsky, MD Gives an Update on the CheckMate 274 Trial

Episode 221: ASCO GU 2023: Matt Galsky, MD Gives an Update on the CheckMate 274 Trial

Matt Galsky, MD discusses several abstracts presented at the 2023 ASCO GU Cancers Symposium on perioperative nivolumab for urothelial cancer, including an update on the CheckMate 274 trial that examined adjuvant nivolumab versus placebo in patients with high-risk muscle invasive urothelial cancer after radical surgery. Dr. Galsky is the Director of Genitourinary Medical Oncology at The Tisch Cancer Institute and Professor of Medicine at the Icahn School of Medicine at Mount Sinai.

Feb 17, 202330:14
Episode 220: ASCO GU 2023: Discussing PARPi for CRPC with Michael Morris, MD

Episode 220: ASCO GU 2023: Discussing PARPi for CRPC with Michael Morris, MD

The Uromigos met with Michael Morris, MD while at the 2023 ASCO GU Cancers Symposium to discuss PARP inhibition for castration-resistant prostate cancer and the differing opinions on how and when it should be utilized. Dr. Morris is a prostate cancer specialist and researcher, and the Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center.

Feb 17, 202325:20
Episode 219: ASCO GU 2023: Neeraj Agarwal, MD, FASCO Discusses the TALAPRO-2 study

Episode 219: ASCO GU 2023: Neeraj Agarwal, MD, FASCO Discusses the TALAPRO-2 study

Neeraj Agarwal, MD, FASCO, describes the data from the TALAPRO-2 study on combination talazoparib and enzalutamide for metastatic castration-resistant prostate cancer as presented at the 2023 ASCO GU Cancers Symposium. Dr. Agarwal is a medical oncologist and Presidential Endowed Chair at Huntsman Cancer Institute, as well as editor-in-chief for ASCO Daily News.

Feb 17, 202322:10
Episode 218: Discussing The Cost of Cancer Drugs With Daniel Goldstein, MD

Episode 218: Discussing The Cost of Cancer Drugs With Daniel Goldstein, MD

The Uromigos discuss the cost of quality adjusted life years with Daniel Goldstein, MD, Senior Physician at the Davidoff Cancer Center of Rabin Medical Center. Dr. Goldstein specializes in the treatment of prostate, bladder, kidney and testicular cancers.

Feb 07, 202325:50
Episode 217: Rising Star: Vadim Koshkin and ADCs

Episode 217: Rising Star: Vadim Koshkin and ADCs

Peter O'Donnell makes a guest appearance.
Feb 03, 202318:30
Episode 216: ADCs in Bladder Cancer With Petros Grivas, MD, PhD

Episode 216: ADCs in Bladder Cancer With Petros Grivas, MD, PhD

Petros Grivas, MD, PhD joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer, including enfortumab vedotin (EV) and the results of the drug's EV-301 trial. The combination treatment of EV and pembrolizumab versus chemotherapy alone is also discussed, including the EV-302 trial. Dr. Grivas is a professor in the Division of Medical Oncology at the University of Washington School of Medicine, as well as a physician at Fred Hutch Cancer Center.

Jan 30, 202325:47
Episode 215: Resumen cáncer de próstata y vejiga reunión Canarias

Episode 215: Resumen cáncer de próstata y vejiga reunión Canarias

Resumen cáncer de próstata y vejiga reunión Canarias
Jan 21, 202327:12
Episode 214: Resumen de la reunión en las Islas Canarias sobre cáncer renal

Episode 214: Resumen de la reunión en las Islas Canarias sobre cáncer renal

Resumen de la reunión en las Islas Canarias sobre cáncer renal
Jan 21, 202321:32